申请人:Yamanouchi Pharmaceutical Co., Ltd.
公开号:US05521180A1
公开(公告)日:1996-05-28
A morpholine derivative represented by formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.3, which may be the same or different, each represent a hydrogen atom or a lower alkyl group; R.sup.2 represents a halogen atom; and the dotted line indicates an optional double bond. These compounds exhibit a selective 5-HT reuptake inhibitory activity and a selective 5-HT.sub.2 receptor antagonistic activity and useful as a therapeutic agent for depression, anxiety, etc. with reduced side effects.
以式子(I)表示的吗啡啶衍生物或其药学上可接受的盐:
其中,R1和R3(可以相同也可以不同)分别表示氢原子或较低的烷基;R2表示卤原子;虚线表示可选的双键。这些化合物表现出选择性5-HT再摄取抑制活性和选择性5-HT2受体拮抗活性,并且可用作治疗抑郁症、焦虑等疾病的治疗剂,具有减少副作用的作用。